CROSSJECT advances in the development of ZEPIZURE® Junior for children

CROSSJECT announces it has reached a significant milestone in the development of ZEPIZURE® Junior, its solution for childhood epileptic seizures. This product is based on ZENEO® needle-free auto-injector technology and specifically targets the pediatric population. A recent clinical ultrasound study helped calibrate the injection depth appropriate for children.

In the United States, approximately 456,000 children have active epilepsy, requiring urgent care. CROSSJECT has conducted extensive research, including clinical and experimental testing, confirming the efficacy and safety of ZENEO® in junior mode.

The company's commitment to pediatrics is reinforced by strategic partnerships with institutions such as BARDA. The goal is to make ZEPIZURE® a standard in the treatment of childhood epileptic seizures. CROSSJECT continues its discussions with the FDA for the approval of concrete solutions for pediatric patients.